Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Dillon

Showing results (141-150 of 151) with videos related to

Pageof 16
Sort By:
The Oncologist|January 18, 2019
Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid SyndromeLowell B Anthony, Matthew H Kulke, Martyn E Caplin, et al.
Annals of Surgical Oncology|September 13, 2021
Management of Duodenal Neuroendocrine Tumors: Surgical versus Endoscopic Mucosal ResectionCatherine G Tran, Scott K Sherman, Mohammed O Suraju, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 4, 2017
Localization of Unknown Primary Site with <sup>68</sup>Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine TumorYusuf Menda, Thomas M O'Dorisio, James R Howe, et al.
Plos Biology|February 27, 2019
Time-dependent Pax3-mediated chromatin remodeling and cooperation with Six4 and Tead2 specify the skeletal myogenic lineage in developing mesodermAlessandro Magli, June Baik, Lauren J Mills, et al.
American Journal of Medical Genetics. Part A|March 2, 2021
Presacral neuroendocrine tumors associated with the Currarino syndromeAaron T Scott, Jonathon B Tessmann, Terry Braun, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 7, 2018
Efficacy and Safety of High-Specific-Activity <sup>131</sup>I-MIBG Therapy in Patients with Advanced Pheochromocytoma or ParagangliomaDaniel A Pryma, Bennett B Chin, Richard B Noto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine TumorsAaron T Scott, Michelle Weitz, Patrick J Breheny, et al.
Pancreas|June 14, 2017
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine TumorsJonathan R Strosberg, Thorvardur R Halfdanarson, Andrew M Bellizzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
High-Specific-Activity-<sup>131</sup>I-MIBG versus <sup>177</sup>Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and ParagangliomaAbhishek Jha, David Taïeb, Jorge A Carrasquillo, et al.
Journal of the National Cancer Institute|March 11, 2026
Quality of life and care experiences in a US multi-institutional neuroendocrine tumor cohortMichael A O'Rorke, Tao Xu, Rhonda R Decook, et al.
Pageof 16

Showing results (141-150 of 151) with videos related to

Sort By:
Pageof 16
The Oncologist|January 18, 2019
Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid SyndromeLowell B Anthony, Matthew H Kulke, Martyn E Caplin, et al.
Annals of Surgical Oncology|September 13, 2021
Management of Duodenal Neuroendocrine Tumors: Surgical versus Endoscopic Mucosal ResectionCatherine G Tran, Scott K Sherman, Mohammed O Suraju, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 4, 2017
Localization of Unknown Primary Site with <sup>68</sup>Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine TumorYusuf Menda, Thomas M O'Dorisio, James R Howe, et al.
Plos Biology|February 27, 2019
Time-dependent Pax3-mediated chromatin remodeling and cooperation with Six4 and Tead2 specify the skeletal myogenic lineage in developing mesodermAlessandro Magli, June Baik, Lauren J Mills, et al.
American Journal of Medical Genetics. Part A|March 2, 2021
Presacral neuroendocrine tumors associated with the Currarino syndromeAaron T Scott, Jonathon B Tessmann, Terry Braun, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 7, 2018
Efficacy and Safety of High-Specific-Activity <sup>131</sup>I-MIBG Therapy in Patients with Advanced Pheochromocytoma or ParagangliomaDaniel A Pryma, Bennett B Chin, Richard B Noto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine TumorsAaron T Scott, Michelle Weitz, Patrick J Breheny, et al.
Pancreas|June 14, 2017
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine TumorsJonathan R Strosberg, Thorvardur R Halfdanarson, Andrew M Bellizzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
High-Specific-Activity-<sup>131</sup>I-MIBG versus <sup>177</sup>Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and ParagangliomaAbhishek Jha, David Taïeb, Jorge A Carrasquillo, et al.
Journal of the National Cancer Institute|March 11, 2026
Quality of life and care experiences in a US multi-institutional neuroendocrine tumor cohortMichael A O'Rorke, Tao Xu, Rhonda R Decook, et al.
Pageof 16